In this registry study,(1) 50 subjects prone to blood vessel challenge were treated with Meriva® (1g/day) to evaluate its ability to support healthy blood vessels.
Participants were divided in two groups. The first one received Meriva® for 4 weeks while the second group was used as a control. The presence and evolution of endothelial challenge was measured instrumentally (laser doppler flowmetry, pO2) and observationally (evaluation of the foot), after 4 weeks of treatment, the Meriva® group showed an amelioration of all the parameters investigated, as well as a general amelioration of the quality of life, as measured by the Karnofsky scale.
Furthermore, in a previous reported pilot study(2), 38 subjects prone to blood vessel challenge were administered with 1 g/day of Meriva (in addition to the standard management plan) for at least 4 weeks.
Compared to the control group (n=39), following the standard management plan alone, the Meriva® group showed a statistically significant improvement in the vessel response (p<0.05) and the decrease in the score of the peripheral vessel challenge (p<0.05).
(1) Appendino G. et al., Panminerva Med. 2011 Sep;53(3 Suppl 1):43-9.
(2) Steigerwalt R., Nebbioso M., Appendino G., Belcaro G., Ciammaichella G., Cornelli U., Luzzi R., Togni S., Dugall M., Cesarone M. R., Ippolito E., Errichi B. M., Ledda A., Hosoi M., Corsi M., Panminerva Med. 2012 54 (Suppl. 1 to No. 4): 11-6